Protara Therapeutics, Inc.
General ticker "TARA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $187.7M (TTM average)
Protara Therapeutics, Inc. follows the US Stock Market performance with the rate: 38.0%.
Estimated limits based on current volatility of 2.9%: low 4.33$, high 4.59$
Factors to consider:
- Total employees count: 33 (+22.2%) as of 2024
- Top business risk factors: Limited operating history, Program cancellation risk, Market competition, License dependency, Manufacturing risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.57$, 7.38$]
- 2026-12-31 to 2027-12-31 estimated range: [3.08$, 6.58$]
Financial Metrics affecting the TARA estimates:
- Positive: with PPE of -4.1 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
Short-term TARA quotes
Long-term TARA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $43.61MM | $49.15MM | $64.55MM |
| Operating Income | $-43.61MM | $-49.15MM | $-64.55MM |
| Non-Operating Income | $3.19MM | $4.56MM | $7.11MM |
| R&D Expense | $24.99MM | $31.70MM | $42.63MM |
| Income(Loss) | $-40.42MM | $-44.60MM | $-57.44MM |
| Net Income(Loss)* | $-40.42MM | $-44.60MM | $-57.44MM |
| Stockholders Equity | $68.32MM | $167.13MM | $196.41MM |
| Assets | $78.95MM | $181.45MM | $209.47MM |
| Operating Cash Flow | $-37.56MM | $-35.81MM | $-56.37MM |
| Capital expenditure | $0.04MM | $0.06MM | $0.09MM |
| Investing Cash Flow | $53.11MM | $19.16MM | $-139.49MM |
| Financing Cash Flow | $-0.09MM | $139.87MM | $82.72MM |
| Earnings Per Share** | $-3.57 | $-2.17 | $-1.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.